NASDAQ:EVGN

Evogene Stock Forecast, Price & News

$4.14
+0.04 (+0.98 %)
(As of 04/20/2021 12:42 PM ET)
Add
Compare
Today's Range
$3.96
Now: $4.14
$4.29
50-Day Range
$4.26
MA: $4.96
$6.18
52-Week Range
$0.94
Now: $4.14
$10.24
Volume27,103 shs
Average Volume1.58 million shs
Market Capitalization$106.61 million
P/E RatioN/A
Dividend YieldN/A
Beta1.43
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through big data and artificial intelligence, designed to computationally discover and uniquely guide the development of life-science products based on microbes, small molecules, and genetic elements. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Industrial Application segment develops enhanced castor bean seeds to serve as a feedstock source for biofuel and other industrial uses. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and multi drug resistant organisms. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer; and through its subsidiary, Canonic Ltd., has a collaboration agreement with Cannbit Ltd., a subsidiary of Tikun Olam-Cannbit Ltd. for the development of novel medical cannabis products. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.
Evogene logo

Industry, Sector and Symbol

Industry Agricultural chemicals
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EVGN
CUSIPN/A
Phone972-8931-1900
Employees143
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$750,000.00
Book Value$2.34 per share

Profitability

Net Income$-18,110,000.00
Net Margins-2,649.69%

Miscellaneous

Market Cap$106.61 million
Next Earnings Date5/25/2021 (Estimated)
OptionableNot Optionable

Headlines

Evogene to Hold Virtual Investor & Analyst Days
April 7, 2021 |  finance.yahoo.com
Short Interest in Evogene Ltd. (NASDAQ:EVGN) Drops By 38.6%
March 30, 2021 |  americanbankingnews.com
Evogene Reports Fourth Quarter and Full Year 2020 Financial Results
March 3, 2021 |  markets.businessinsider.com
Cannbit - Benzinga
February 24, 2021 |  benzinga.com
See More Headlines

MarketRank

Overall MarketRank

1.29 out of 5 stars

Medical Sector

827th out of 2,018 stocks

Agricultural Chemicals Industry

8th out of 20 stocks

Analyst Opinion: 3.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
$4.14
+0.04 (+0.98 %)
(As of 04/20/2021 12:42 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive EVGN News and Ratings via Email

Sign-up to receive the latest news and ratings for EVGN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Evogene (NASDAQ:EVGN) Frequently Asked Questions

Is Evogene a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Evogene in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Evogene stock.
View analyst ratings for Evogene
or view top-rated stocks.

What stocks does MarketBeat like better than Evogene?

Wall Street analysts have given Evogene a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Evogene wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Evogene?

Evogene saw a decrease in short interest in the month of March. As of March 15th, there was short interest totaling 854,100 shares, a decrease of 38.6% from the February 28th total of 1,390,000 shares. Based on an average daily volume of 1,970,000 shares, the short-interest ratio is currently 0.4 days. Currently, 2.6% of the company's stock are sold short.
View Evogene's Short Interest
.

When is Evogene's next earnings date?

Evogene is scheduled to release its next quarterly earnings announcement on Tuesday, May 25th 2021.
View our earnings forecast for Evogene
.

How were Evogene's earnings last quarter?

Evogene Ltd. (NASDAQ:EVGN) posted its quarterly earnings data on Tuesday, March, 2nd. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by $0.08. The biotechnology company earned $0.35 million during the quarter. Evogene had a negative net margin of 2,649.69% and a negative trailing twelve-month return on equity of 38.40%.
View Evogene's earnings history
.

How has Evogene's stock price been impacted by COVID-19?

Evogene's stock was trading at $0.99 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, EVGN shares have increased by 324.2% and is now trading at $4.20.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for EVGN?

1 brokers have issued twelve-month price objectives for Evogene's stock. Their forecasts range from $9.00 to $9.00. On average, they expect Evogene's share price to reach $9.00 in the next twelve months. This suggests a possible upside of 114.3% from the stock's current price.
View analysts' price targets for Evogene
or view top-rated stocks among Wall Street analysts.

Who are Evogene's key executives?

Evogene's management team includes the following people:
  • Mr. Ofer Haviv, CEO, Pres & Director (Age 55, Pay $442k)
  • Ms. Dorit Kreiner, Chief Financial Officer
  • Mr. Mark Kapel, Exec. VP of Technology (Age 44, Pay $234k)
  • Dr. Eyal Emmanuel, Chief Scientific Officer (Age 48)
  • Rivka Neufeld, Investor Relation & PR Mang.
  • Sassi Masliah, VP of Legal Affairs & Company Sec.
  • Mr. Douglas A. Eisner, Chief Exec. Officer of AgPlenus Ltd.

Who are some of Evogene's key competitors?

What other stocks do shareholders of Evogene own?

What is Evogene's stock symbol?

Evogene trades on the NASDAQ under the ticker symbol "EVGN."

How do I buy shares of Evogene?

Shares of EVGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Evogene's stock price today?

One share of EVGN stock can currently be purchased for approximately $4.20.

How much money does Evogene make?

Evogene has a market capitalization of $108.15 million and generates $750,000.00 in revenue each year. The biotechnology company earns $-18,110,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis.

How many employees does Evogene have?

Evogene employs 143 workers across the globe.

What is Evogene's official website?

The official website for Evogene is www.evogene.com.

Where are Evogene's headquarters?

Evogene is headquartered at 13 GAD FEINSTEIN STREET PARK REHOVOT P.O.B 2100, REHOVOT L3, 76121.

How can I contact Evogene?

Evogene's mailing address is 13 GAD FEINSTEIN STREET PARK REHOVOT P.O.B 2100, REHOVOT L3, 76121. The biotechnology company can be reached via phone at 972-8931-1900 or via email at [email protected]


This page was last updated on 4/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.